Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead Inks Gene Editing Collaboration Deal for HBV Infection

Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.

    Company News For Sep 13, 2018

    Companies in the news are: GILD, VZ, BHC and WBC

      Gilead's Rheumatoid Arthritis Drug Successful in Phase III

      Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secondary endpoints in first phase III study.

        Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars

        Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.

          Merck's Antibacterial Drug Succeeds in Label Expansion Study

          Merck's (MRK) label expansion study evaluating its antibacterial drug, Zerbaxa for two types of pneumonia infections meets primary endpoints.

            Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA

            The FDA will review Regeneron (REGN) and Sanofi's sBLA for its PCSK9 Inhibitor Praluent to reduce risk of major adverse cardiovascular events.

              Incyte, Foundation Medicine Partner for Companion Diagnostics

              Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.

                Endocyte Announces FDA's Acceptance of Trial Endpoint Change

                177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients

                  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

                  Gilead Sciences (GILD) closed the most recent trading day at $72.51, moving +0.36% from the previous trading session.

                    Shire's ADHD Portfolio Remains Strong Amid Competition

                    Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.

                      Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

                      Inovio (INO) focuses on the development of its most advanced candidate, VGX-3100 vaccine, which has been progressing well. Its collaboration with big pharma companies exhibits strong growth.

                        The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE

                        The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE

                          Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine

                          Inovio Pharmaceuticals (INO) administers dosage in the first patient under a phase I/IIa trial to assess its MERS vaccine INO-4700.

                            Mark Vickery headshot

                            Top Research Reports for Abbott, Gilead & FedEx

                            Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Gilead (GILD) and FedEx (FDX).

                              bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy

                              bluebird bio (BLUE) announces updated results from phase II/III Starbeam study of its Lenti-D gene therapy in boys aged 17 years or below with CALD.

                                Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint

                                Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.

                                  ProQR Up More Than 120% on Favorable Eye Disorder Study Data

                                  ProQR Therapeutics (PRQR) presents positive data from a phase I/II study on QR-110, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.

                                    Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx

                                    Puma Biotech (PBYI) gains EU approval for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

                                      Horizon Pharma Completes Enrollment in Eye Disease Study

                                      Horizon Pharma (HZNP) completes early enrollment for the confirmatory phase III study of teprotumumab, which is being evaluated for the treatment of thyroid eye disease.

                                        Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout

                                        Bayer (BAYRY) misses earnings estimates in the second quarter of 2018. The company completes the acquisition of Monsanto for $63 billion.

                                          MannKind Stock Up on Licensing Deal With United Therapeutics

                                          MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.

                                            Alnylam's Shares Up as Onpattro Gets FDA and EU Approvals

                                            Shares of Alnylam (ALNY) increase due to the FDA and European approval for Onpattro.

                                              Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)

                                              Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

                                                Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine

                                                Inovio Pharmaceuticals (INO) and Korean partner GeneOne Life Science dose the first patient in a phase I study, which will assess its hepatitis C vaccine GLS-6150.

                                                  AstraZeneca's Lupus Drug Misses Primary Endpoint in Study

                                                  AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.